Monday, June 21, 2010 6:39:08 PM
Imaging3 did not hold anything back from investors. They submitted exactly what they said they submitted. However, the FDA may be treating it as an initial submission (90 day review period), because it's the first submission that was made to the new review team, or they may be treating it as a submission in response to the first additional information action (75 day review period), because it was submitted in response to their first set of questions / requests. Either way, 90-days is the outside mark for the FDA's INTERNAL GUIDELINES / GOALS. Remember, and this is something that my 5 year old nephew understands but many here seem not to be able to grasp, these review cycles ARE NOT DEADLINES. They are just goals, and if the FDA misses these goals, which they do 10% of the time, there is no recourse for the applicant. It's nice to have a day circled on your calendar because it helps you stay sane through this agonizing process, but it is what it is... a goal, not a deadline.
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM